ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia

Trial Profile

ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Roxadustat (Primary) ; Darbepoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 25 Jul 2016 Primary endpoint (Haemoglobin level) has been met, as reported in an Astellas Pharma media release.
    • 25 Jul 2016 Results published in an Astellas Pharma media release.
    • 22 Oct 2014 Last checked against ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top